Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Abstract The treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) with nilotinib has resulted in a higher rate of major molecular (MMR) and complete cytogenetic response (CCyR) at 12 months compared to imatinib but at a higher cumulative cost and increased risk of serious advers...

Celý popis

Podrobná bibliografie
Hlavní autoři: Ali Ibrahim, Nour Moukalled, Rami Mahfouz, Jean El Cheikh, Ali Bazarbachi, Iman Abou Dalle
Médium: Článek
Jazyk:English
Vydáno: SAABRON PRESS 2022-05-01
Edice:Clinical Hematology International
Témata:
CML
Chronic phase
Imatinib
Nilotinib
Cytogenetic response
Maintenance therapy
On-line přístup:https://doi.org/10.1007/s44228-022-00001-x

Internet

https://doi.org/10.1007/s44228-022-00001-x

Podobné jednotky